Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

Metastatic Prostate Cancer Clinical Trial

Official title:

Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06050239
• Other study ID #: KY20221124-06
• Status: Recruiting
• Phase: Early Phase 1
• Start date: March 1, 2023
• Est. completion date: March 1, 2025

Study information

• Verified date: September 2023
• Source: Nanjing First Hospital, Nanjing Medical University
• Contact: Feng Wang
• Phone: 02552271491
• Email: fengwangcn[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness and safety of 177Lu-PSMA-0057 in metastatic prostate cancer.

Description:

This study is a prospective, single arm, open exploratory clinical study. Ten patients with metastatic prostate cancer confirmed by histopathology will be included in the group. Before conducting any research specific screening evaluation, participants must sign an Informed Consent Form (ICF). All screening procedures must be completed within 28 days before the first day of administration (D1). During the screening period, patients will be scanned using 68Ga-PSMA-0057 to determine the PSMA expression status. It is recommended to perform a 68Ga-PSMA-0057 scan after confirming all other qualification requirements. The successfully screened subjects underwent baseline examination 1 day before administration (D-1) (The laboratory examination and ECG are limited to the examination data within 7 days of our hospital, while imaging is limited to the data within 28 days of our hospital), and were confirmed to meet the enrollment requirements before enrollment. The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks. After the safety evaluation, the subjects may temporarily leave the research institution. At the end of the second treatment cycle, the improved RECIST version 1.1/PCWG3 criterion was used to rate the tumor remission. Perform CT/MRI and other imaging examinations at the screening period, the end of the second treatment cycle, and at the end of treatment/early termination of the visit (those who have undergone CT/MRI and other imaging examinations within 28 days before the end of treatment/early termination of the visit may be exempted). Perform prostatic specific antigen(PSA) assessment at the end of the second treatment cycle to determine and confirm PSA response. Conduct comprehensive safety checks at baseline, end of treatment visit/early termination visit, including vital signs, physical examination, laboratory examination (including blood routine, blood biochemistry, coagulation function, urine routine), total serum PSA level, serum testosterone measurement, ECG examination, and echocardiography. Safety check after administration: ① ECG examination: Weekly blood routine check after administration in cycles 1 and 2; ② Blood routine examination: After the first and second cycles of administration, weekly blood routine examination is conducted; ③ Blood biochemistry, coagulation function, and urine routine examination: After administration in the first cycle, blood biochemistry, coagulation function, and urine routine examination should be rechecked every week, and once at the end of the second cycle; ④ Echocardiography: Recheck once at the end of the second cycle.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: March 1, 2025
• Est. primary completion date: March 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male, age>18 years old;
• The expected life must be>9 months (determined by the researcher);
• Eastern Cooperative Oncology Group(ECOG) score 0-2 points;
• Suffering from prostate adenocarcinoma confirmed by histological or cytological examination (current or previous prostate and/or metastatic site biopsy);
• Patients with high PSMA uptake (standardized uptake value (SUV) max = salivary gland or proximal small intestine, or SUVmax = 12) at the lesion site displayed on 68Ga-PSMA-0057 positron emission tomography / computer tomography(PET/CT) scan, and without FDG positive but PSMA negative lesions;
• There are diagnostic documents confirming metastatic prostate cancer;
• The patient must have = 1 detectable metastatic lesion in the bone and/or soft tissue/visceral area, which is present on baseline CT, MRI, or bone scan imaging obtained = 28 days prior to the start of study treatment;
• Lymphatic and skeletal metastases or visceral metastases that cannot be removed through surgery;
• After ADT treatment, the disease continues to progress;
• The patient must have recovered to = 2 levels from all clinically significant toxicity associated with previous treatments (i.e. chemotherapy, radiotherapy, immunotherapy, etc.);
• The functions of important organs meet the following requirements:

1. Bone marrow reserve: White blood cell (WBC) count = 2.5 × 10 ^ 9/L or absolute neutrophil count (ANC) = 1.5 x 10 ^ 9/L; Platelet count = 100 x 10 ^ 9/L; Hemoglobin = 90g/L.

2. Liver: Total bilirubin = 2 times the upper limit of normal value (ULN) (excluding subjects confirmed to have Gilbert's disease, no more than 10 times the ULN is sufficient); AST and ALT: = 2 times ULN for those without liver metastasis or = 3 times ULN for those with liver metastasis.

3. Kidney: Serum/plasma creatinine = 1.5 times ULN or creatinine clearance rate = 50 mL/min.

• Albumin>25 g/L;
• Agree to use appropriate methods of contraception during the study period and within 1 month after the end of administration;
• Signed informed consent form.

Exclusion Criteria:

• Received radioisotope diagnosis or treatment (such as 89Sr, 153Sm, 186Re, 188Re, 223Ra) before enrollment, or received PSMA targeted radioligand therapy;
• Received systemic anti prostate cancer treatment such as chemotherapy, PARP inhibitors, immunotherapy or biotherapy (including monoclonal antibodies) within 28 days prior to enrollment;
• Received any other study drug diagnosis/treatment within 28 days prior to enrollment, unless it is an observational (non intervention) clinical study or an intervention clinical study follow-up;
• Other accompanying cytotoxic chemotherapy, immunotherapy, radioligand therapy, or investigational therapy;
• Known to be allergic to any research treatment or its excipients, or to drugs of similar chemical categories;
• Unable to lie flat, remain stationary, or tolerate PET/CT imaging;
• Severe urinary incontinence, hydronephrosis, severe urinary dysfunction, or the need for indwelling a catheter for any reason;
• There are contraindications to furosemide, including known allergies or intolerance to furosemide or sulfonamide drugs;
• Patients with central nervous system (CNS) metastasis accompanied by neurological instability or symptoms or receiving corticosteroids to maintain neurological integrity. If epidural diseases, spinal canal diseases, and previously affected areas of the spinal cord have been treated, stabilized, and have no neurological damage, they are eligible to participate in the study. For patients with a history of CNS metastasis to the brain parenchyma (or CNS metastasis), baseline and subsequent radiological imaging must include brain evaluation (preferably magnetic resonance imaging (MRI) or enhanced CT); Note: Patients with a history of CNS metastasis who have previously received treatment, have stable neurological function, are asymptomatic, and have not received corticosteroid treatment are allowed to be included in the group.
• Diagnosed as other malignant tumors that are expected to change life expectancy or may interfere with disease assessment. However, patients with a past history of malignant tumors, who have been fully treated and have no disease for more than 3 years are eligible to participate in the study, and patients with fully treated non melanoma skin cancer and superficial bladder cancer are also eligible to participate in the study;
• The presence of clinically significant active heart disease is defined as any of the following: Within 6 months before signing the ICF, New York Heart Association(NYHA) grade 3/4 congestive heart failure, unless improved after treatment, and if the echocardiogram shows ejection fraction(EF) >45%, the symptoms improve to<grade 3; Previous or current diagnosis of ECG abnormalities indicates significant safety risks for study participants, such as accompanying clinically significant arrhythmias such as persistent ventricular tachycardia, complete left bundle branch block, and high degree atrioventricular (AV) block (such as double bundle branch block, Mobitz II type, and third degree atrioventricular block); A family history of familial long QT syndrome or known family history of torsade de pointe ventricular tachycardia; Cardiac abnormalities or cardiac repolarization abnormalities, including any of the following: a history of myocardial infarction (MI), angina pectoris, or coronary artery bypass grafting (CABG) within 6 months prior to signing the ICF.
• Complicated with any serious and/or uncontrollable diseases or other diseases that may affect the subject's participation in this study as determined by the investigator, as follows: Uncontrolled diseases (such as hypertension patients' blood pressure = 150/100 mmHg or diabetes patients' fasting blood glucose = 8mmol/L or 2h after meal blood glucose = 11mmol/L); Life threatening autoimmune and ischemic diseases; Suffering from any other disease that may increase the risk of toxic reactions (such as nephrotic syndrome, uremia, acute or severe cholinergic syndrome, etc.); Clinically severe gastrointestinal dysfunction, including active ulcerative colitis, intestinal obstruction, intestinal bleeding, diarrhea, Crohn's disease, or the need for intravenous nutrition treatment;
• The disease progresses rapidly and the expected survival period is less than or equal to 3 months;
• Known to have bilateral hip joint prostheses;
• Positive individuals with Immunodeficiency virus antibodies(HIV-Ab) or treponema pallidum antibody(TPAb) during the screening period (examination);
• Complicated serious (determined by the main investigator) medical diseases, including but not limited to uncontrolled infections, known active hepatitis B or C, or other major comorbidities that the investigator believes may harm research participation or cooperation;
• A history of physical or mental illness/condition that may interfere with the purpose and evaluation of the study;
• Symptomatic spinal cord compression, or clinical or radiological findings indicating imminent spinal cord compression;
• Any situation that hinders the position of raising the arm;
• According to the judgment of the researchers, there are other factors that may lead to the subject being forced to terminate the study midway, such as non-compliance with the protocol, suffering from other serious illnesses (including mental illness) that require concurrent treatment, clinically significant laboratory test values that are severely abnormal, family or social factors that may affect the safety of the subject or the collection of experimental data.

Related Conditions & MeSH terms

• Metastatic Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• 177Lu-PSMA-0057
The enrolled subjects will be administrated with 177Lu-PSMA-0057, and then enter the post administration observation phase while completing safety checks.

Locations

Country	Name	City	State
China	Nanjing First Hospital	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Nanjing First Hospital, Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PSA dynamic	PSA50 response rate, PSA90 response rate: PSA response determined by measuring a decrease of = 50% or = 90% in PSA levels from baseline to baseline, and reassessed at least 3 weeks later. The proportion of patients with a decrease of = 50% or 90% in PSA response rate at a certain time point is usually used as an evaluation indicator.; PSA undetectable rate: refers to the percentage of patients with PSA detectable at baseline (= 0.2ng/mL) but undetectable during the study period (<0.2 ng/mL).	2 weeks
Secondary	Radiographic Progression Free Survival,rPFS	The response status of tumors will be evaluated using the modified RECIST version 1.1/PCWG3 standard: solid tumors typically use the conventional RECIST 1.1 standard to evaluate tumor remission or progression. Advanced prostate cancer has a high proportion of bone metastases. According to RECIST 1.1, bone metastases are usually classified as unmeasurable lesions and are not evaluated as target lesions. Instead, bone scans are evaluated using the PCWG3 standard.; RPFS is defined as the time from the random date to the occurrence of imaging progression or death from any cause, whichever occurs first. Imaging progression includes the evaluation of the progression of primary lesions, non regional lymph node invasion, soft tissue metastasis, and bone metastasis according to the RECIST 1.1 and PCWG3 standards, and is determined by the central reviewer or investigator review.	12 weeks